331 related articles for article (PubMed ID: 38037114)
21. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.
Hung SI; Chu MT; Hou MM; Lee YS; Yang CK; Chu SY; Liu FY; Hsu HC; Pao SC; Teng YC; Chen CB; Chao A; Chung WH; Chang JW; Lai CH
Biomed Pharmacother; 2023 Dec; 169():115928. PubMed ID: 38011788
[TBL] [Abstract][Full Text] [Related]
22. Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research.
Wang Z; Cao YJ
Front Immunol; 2020; 11():176. PubMed ID: 32194541
[TBL] [Abstract][Full Text] [Related]
23. Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R; Tran E; Deniger DC; Gros A; Pasetto A; Parkhurst MR; Gartner JJ; Prickett TD; Cafri G; Robbins PF; Rosenberg SA
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282837
[TBL] [Abstract][Full Text] [Related]
24. How does TCR-T cell therapy exhibit a superior anti-tumor efficacy.
Yang D; Duan Z; Yuan P; Ding C; Dai X; Chen G; Wu D
Biochem Biophys Res Commun; 2023 Dec; 687():149209. PubMed ID: 37944471
[TBL] [Abstract][Full Text] [Related]
25. Adoptive Immunotherapy beyond CAR T-Cells.
Titov A; Zmievskaya E; Ganeeva I; Valiullina A; Petukhov A; Rakhmatullina A; Miftakhova R; Fainshtein M; Rizvanov A; Bulatov E
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670139
[TBL] [Abstract][Full Text] [Related]
26. Detection of mutant antigen-specific T cell receptors against multiple myeloma for T cell engineering.
Okada M; Shimizu K; Nakazato H; Yamasaki S; Fujii SI
Mol Ther Methods Clin Dev; 2023 Jun; 29():541-555. PubMed ID: 37359417
[TBL] [Abstract][Full Text] [Related]
27. Targeting KRAS
Ai Q; Li F; Zou S; Zhang Z; Jin Y; Jiang L; Chen H; Deng X; Peng C; Mou N; Wen C; Shen B; Zhan Q
Front Immunol; 2023; 14():1161538. PubMed ID: 37287989
[TBL] [Abstract][Full Text] [Related]
28. Tumor neoantigens: from basic research to clinical applications.
Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
[TBL] [Abstract][Full Text] [Related]
29. Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy.
Shao W; Yao Y; Yang L; Li X; Ge T; Zheng Y; Zhu Q; Ge S; Gu X; Jia R; Song X; Zhuang A
Exp Hematol Oncol; 2024 Apr; 13(1):37. PubMed ID: 38570883
[TBL] [Abstract][Full Text] [Related]
30. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
31. Structural basis for T cell recognition of cancer neoantigens and implications for predicting neoepitope immunogenicity.
Mariuzza RA; Wu D; Pierce BG
Front Immunol; 2023; 14():1303304. PubMed ID: 38045695
[TBL] [Abstract][Full Text] [Related]
32. Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches.
Huang R; Zhao B; Hu S; Zhang Q; Su X; Zhang W
Biomark Res; 2023 Apr; 11(1):41. PubMed ID: 37062844
[TBL] [Abstract][Full Text] [Related]
33. Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires.
Grunert C; Willimsky G; Peuker CA; Rhein S; Hansmann L; Blankenstein T; Blanc E; Beule D; Keller U; Pezzutto A; Busse A
Cancers (Basel); 2022 Apr; 14(7):. PubMed ID: 35406613
[TBL] [Abstract][Full Text] [Related]
34. Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy.
Plewa N; Poncette L; Blankenstein T
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822673
[TBL] [Abstract][Full Text] [Related]
35. Neoantigen vaccine and neoantigen-specific cell adoptive transfer therapy in solid tumors: Challenges and future directions.
Shen Y; Yu L; Xu X; Yu S; Yu Z
Cancer Innov; 2022 Aug; 1(2):168-182. PubMed ID: 38090649
[TBL] [Abstract][Full Text] [Related]
36. Creating an Innovative Artificial Intelligence-Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial.
Bujak J; Kłęk S; Balawejder M; Kociniak A; Wilkus K; Szatanek R; Orzeszko Z; Welanyk J; Torbicz G; Jęckowski M; Kucharczyk T; Wohadlo Ł; Borys M; Stadnik H; Wysocki M; Kayser M; Słomka ME; Kosmowska A; Horbacka K; Gach T; Markowska B; Kowalczyk T; Karoń J; Karczewski M; Szura M; Sanecka-Duin A; Blum A
JMIR Res Protoc; 2023 Jul; 12():e45872. PubMed ID: 37440307
[TBL] [Abstract][Full Text] [Related]
37. Assessing TCR identity, knock-in efficiency, and potency for individualized TCR-T cell therapy.
Camperi J; Devarajan S; McKay A; Tarighat S; Chen D; Hu Z
J Immunol Methods; 2023 Jun; 517():113491. PubMed ID: 37187316
[TBL] [Abstract][Full Text] [Related]
38. High-affinity oligoclonal TCRs define effective adoptive T cell therapy targeting mutant KRAS-G12D.
Sim MJW; Lu J; Spencer M; Hopkins F; Tran E; Rosenberg SA; Long EO; Sun PD
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12826-12835. PubMed ID: 32461371
[TBL] [Abstract][Full Text] [Related]
39. T Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy.
Sim MJW; Sun PD
Front Immunol; 2022; 13():833017. PubMed ID: 35222422
[TBL] [Abstract][Full Text] [Related]
40. Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression.
Parkhurst M; Gros A; Pasetto A; Prickett T; Crystal JS; Robbins P; Rosenberg SA
Clin Cancer Res; 2017 May; 23(10):2491-2505. PubMed ID: 27827318
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
